PMID- 38310197
OWN - NLM
STAT- MEDLINE
DCOM- 20240205
LR  - 20240206
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 14
IP  - 1
DP  - 2024 Feb 3
TI  - Longitudinal assessment of sweat-based TNF-alpha in inflammatory bowel disease 
      using a wearable device.
PG  - 2833
LID - 10.1038/s41598-024-53522-1 [doi]
LID - 2833
AB  - Wearable devices can non-invasively monitor patients with chronic diseases. Sweat 
      is an easily accessible biofluid for continuous sampling of analytes, including 
      inflammatory markers and cytokines. We evaluated a sweat sensing wearable device 
      in subjects with and without inflammatory bowel disease (IBD), a chronic 
      inflammatory condition of the gastrointestinal tract. Participants with an IBD 
      related hospital admission and a C-reactive protein level above 5 mg/L wore a 
      sweat sensing wearable device for up to 5 days. Tumor necrosis factor-alpha 
      (TNF-alpha) levels were continually assessed in the sweat via the sensor, and daily 
      in the blood. A second cohort of healthy subjects without chronic diseases wore 
      the device for up to 48 h. Twenty-eight subjects were enrolled. In the 16 
      subjects with IBD, a moderate linear relationship between serum and sweat TNF-alpha 
      levels was observed (R(2) = 0.72). Subjects with IBD were found to have a mean 
      sweat TNF-alpha level of 2.11 pg/mL, compared to a mean value of 0.19 pg/mL in 12 
      healthy controls (p < 0.0001). Sweat TNF-alpha measurements differentiated subjects 
      with active IBD from healthy subjects with an AUC of 0.962 (95% CI 0.894-1.000). 
      A sweat sensing wearable device can longitudinally measure key sweat-based 
      markers of IBD. TNF-alpha levels in the sweat of subjects with IBD correlate with 
      serum values, suggesting feasibility in non-invasive disease monitoring.
CI  - (c) 2024. The Author(s).
FAU - Hirten, Robert P
AU  - Hirten RP
AD  - The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Lin, Kai-Chun
AU  - Lin KC
AD  - Bioengineering, University of Texas at Dallas, 800 West Campbell Rd., Richardson, 
      TX, 75080-3021, USA.
FAU - Whang, Jessica
AU  - Whang J
AD  - The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Shahub, Sarah
AU  - Shahub S
AD  - Bioengineering, University of Texas at Dallas, 800 West Campbell Rd., Richardson, 
      TX, 75080-3021, USA.
FAU - Helmus, Drew
AU  - Helmus D
AD  - The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Muthukumar, Sriram
AU  - Muthukumar S
AD  - EnLiSense LLC, Allen, TX, USA.
FAU - Sands, Bruce E
AU  - Sands BE
AD  - The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine 
      at Mount Sinai, New York, NY, USA.
FAU - Prasad, Shalini
AU  - Prasad S
AD  - Bioengineering, University of Texas at Dallas, 800 West Campbell Rd., Richardson, 
      TX, 75080-3021, USA. shalini.prasad@utdallas.edu.
AD  - EnLiSense LLC, Allen, TX, USA. shalini.prasad@utdallas.edu.
LA  - eng
GR  - K23 DK129835/DK/NIDDK NIH HHS/United States
GR  - K23DK129835/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20240203
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Humans
MH  - Tumor Necrosis Factor-alpha
MH  - Sweat
MH  - *Inflammatory Bowel Diseases/diagnosis
MH  - *Wearable Electronic Devices
MH  - Chronic Disease
PMC - PMC10838338
COIS- RPH has served on advisory boards for Bristol Myers Squibb. BES has served as a 
      consultant or received speaker's fees from AbbVie, Abivax, Adiso Therapeutics, 
      Alimentiv, Amgen, Arena Pharmaceuticals, Artizan Biosciences, Artugen 
      Therapeutics, AstraZeneca, Bacainn Therapeutics, Biora Therapeutics, Boehringer 
      Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celltrion 
      Healthcare, ClostraBio, Connect Biopharm, Cytoki Pharma, Eli Lilly and Company, 
      Entera, Evommune, Ferring, Fresenius Kabi, Galapagos, Gilead, Genentech, Glaxo 
      SmithKline, Gossamer Bio, HMP Acquisition, Imhotex, Immunic, InDex 
      Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, 
      Janssen, Johnson & Johnson, Kaleido, Kalyope, Merck, MiroBio, Morphic 
      Therapeutic, MRM Health, OSE Immunotherapeutics, Pfizer, Progenity, Prometheus 
      Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, RedHill 
      Biopharma, Sun Pharma Global, Surrozen, Synlogic Operating Company, Takeda, 
      Target RWE, Theravance Biopharma R&D, TLL Pharmaceutical, USWM Enterprises, 
      Ventyx Biosciences, Viela Bio, and stock options from Ventyx Biosciences. KCL 
      declares no relevant conflicts of interest. JW declares no relevant conflicts of 
      interest. SS declares no relevant conflicts of interest. DH declares no relevant 
      conflicts of interest. SM reports a significant interest in EnLiSense LLC, a 
      company that may have a commercial interest in the results of this research and 
      technology. SP reports a significant interest in EnLiSense LLC, a company that 
      may have a commercial interest in the results of this research and technology.
EDAT- 2024/02/04 00:42
MHDA- 2024/02/05 06:43
PMCR- 2024/02/03
CRDT- 2024/02/03 23:19
PHST- 2023/11/27 00:00 [received]
PHST- 2024/02/01 00:00 [accepted]
PHST- 2024/02/05 06:43 [medline]
PHST- 2024/02/04 00:42 [pubmed]
PHST- 2024/02/03 23:19 [entrez]
PHST- 2024/02/03 00:00 [pmc-release]
AID - 10.1038/s41598-024-53522-1 [pii]
AID - 53522 [pii]
AID - 10.1038/s41598-024-53522-1 [doi]
PST - epublish
SO  - Sci Rep. 2024 Feb 3;14(1):2833. doi: 10.1038/s41598-024-53522-1.